Pfizer completes AstraZeneca’s Small Molecule Anti-Infective business acquisition

Pfizer has announced that it has completed the acquisition of the development and commercialization rights for a late-stage small molecule anti-infective business from AstraZeneca.
 
The deal includes the rights to a trademarked drug recently approved by the EU called Zavicefta, which is aimed at targeting multi-drug resistant Gram-negative infections and could be important in the ever-increasing fight against antibiotic resistance.
 
It also includes development and commercialization rights to Zinforo, which was launched in 2012 and is used to treat patients with complicated skin and soft tissue infections.
 
Group president of Pfizer Essential Health John Young said the deal enhances the company's capabilities in an increasingly important area of therapeutics.
 
"Additionally this acquisition is an example of how we are focusing our investments to drive sustainable revenue growth potential for our Essential Health business," he added.
 
Pfizer was established in 1849 and discovers, develops and provides over 120 different medicines, vaccines and consumer healthcare products globally every year.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.